Skip to main content

Table 1 Patient population characteristics by region (N = 479)

From: General practice patients treated for substance use problems: a cross-national observational study in Belgium

  Flanders (N = 268) Wallonia & Brussels (N = 211) Belgium (N = 479)
  n/N % (95% CI) n/N % (95% CI) n/N % (95% CI)
Men (versus women) 177/267 66.3 (60.3–71.9) 138/207 66.7 (59.8–73.0) 315/474 66.5 (62.0–70.7)
Age in years
 <25 16/268 6.0 (3.5–9.5) 8/211 3.8 (1.7–7.3) 24/479 5.0 (3.2–7.4)
 25–34 40/268 14.9 (10.9–19.8) 42/211 19.9 (14.7–25.9) 82/479 17.1 (13.9–20.8)
 35–44 50/268 18.7 (14.2–23.8) 46/211 21.8 (16.4–28.0) 96/479 20.0 (16.5–23.9)
 45–54 102/268 38.1 (32.2–44.2) 64/211 30.3 (24.2–37.0) 166/479 34.7 (30.4–39.1)
 55–64 60/268 22.4 (17.5–27.9) 51/211 24.2 (18.6–30.5) 111/479 23.2 (19.5–27.2)
Type of substance use
 Alcohol alone 142/268 53.0 (46.8–59.1) 84/211 39.8 (33.1–46.8) 226/479 47.2 (42.6–51.8)
 Prescription drugs 53/268 19.4 (14.8–24.7) 44/211 20.9 (15.6–27.0) 97/479 20.3 (16.5–23.9)
 Illicit drugs, excluding heroin and methadone 54/268 20.1 (15.5–25.5) 26/211 12.3 (8.2–17.5) 80/479 16.7 (13.5–20.3)
 Heroin or methadone 19/268 7.1 (4.3–10.9) 57/211 27.0 (21.1–33.5) 76/479 15.9 (12.7–19.5)
Substance use characteristics
 Abstinence from substances in last 4 weeks 108/268 40.3 (34.4–46.4) 118/211 55.9 (48.9–62.7) 226/479 47.2 (42.6–51.8)
 Single substance use 178/268 66.4 (60.4–72.0) 127/211 60.2 (53.2–61.8) 305/479 63.7 (59.2–68.0)
 Problematic use ≥10 years 102/209 48.8 (41.8–56.0) 111/164 67.9 (59.9–74.8) 213/373 57.1 (51.9–62.2)
Substance-related problems
 Physical problems 149/268 55.6 (49.4–61.6) 84/211 39.8 (33.2–46.8) 233/479 48.6 (44.1–53.2)
 Mental problems 206/268 76.9 (71.3–81.8) 172/211 81.5 (75.6–86.5) 378/479 78.9 (75.0–82.5)
 Problems at work 61/268 22.8 (17.9–28.3) 30/211 14.2 (9.8–19.7) 91/479 19.0 (15.6–22.8)
 Social problems 198/268 73.9 (68.1–79.0) 153/211 72.5 (59.0–78.4) 351/479 73.3 (69.1–77.2)
Occupational status: at work 114/253 45.1 (38.8–51.4) 66/205 32.2 (25.9–39.1) 180/458 39.3 (34.8–43.9)
Treatment history
 First treatment episode 66/249 26.5 (21.1–32.4) 39/188 20.7 (15.2–27.2) 105/437 24.0 (20.1–28.3)
 Ongoing treatment episode 154/254 60.6 (54.3–66.7) 150/210 71.4 (64.8–77.4) 304/464 65.5 (61.0–69.8)
Treatment status at follow-up
 1) Study drop-out, treatment drop-out or deceaseda 93/268 34.7 (29.0–40.7) 64/211 30.3 (24.2–37.0) 157/479 32.8 (28.6–37.2)
 2) Discontinued GP treatment 91/268 34.0 (28.3–40.0) 48/211 22.7 (17.3–29.0) 139/479 29.0 (25.0–33.3)
 3) Continued (usual) GP treatment, substance use treatment by non-GP 19/268 7.1 (4.3–10.9) 9/211 4.3 (2.0–7.9) 28/479 5.8 (3.9–8.3)
 4) Continued substance use treatment by GP & non-GP 33/268 12.3 (8.6–16.9) 40/211 19.0 (13.9–24.9) 73/479 15.2 (12.1–18.8)
 5) Continued substance use treatment by GP alone 32/268 11.9 (8.3–16.4) 50/211 23.7 (18.1–30.0) 82/479 17.1 (13.9–20.8)
Continued GP treatment (total of 3 to 5) 84/268 31.3 (25.8–37.3) 99/211 46.9 (40.0–53.9) 183/479 38.2 (33.8–42.7)
Continued GP substance use treatment (total of 4 and 5) 65/268 24.3 (19.2–29.8) 90/211 42.7 (35.9–49.6) 155/479 32.4 (28.2–36.8)
  1. CI Confidence interval. (Borderline) non-overlapping confidence intervals are in bold
  2. a5 of 479 patients were deceased, 2 deaths were caused by substance use
  3. Missing data: gender: n = 5 (1.0%); age: n = 0; substances used: n = 0; length of use: n = 106 (22.1%); occupational status: n = 21 (4.4%); first treatment: n = 42 (8.8%); ongoing treatment episode: n = 15 (3.1%)